NY-NOVA-CREDIT
28.9.2022 14:01:38 CEST | Business Wire | Press release
Nova Credit, the world’s leading consumer-permissioned credit bureau, today announced that it has partnered with HSBC to provide the bank with global access to its cross-border credit data product, Credit Passport®, creating more opportunities for credit access to cross-border customers across the globe. This partnership will allow HSBC to access the translated credit history of new-to-country consumers as part of their credit applications, upon their permission. This innovative solution will enable the bank to make more real-time application approvals responsibly and at a greater scale. The first deployment, with HSBC Singapore, launched in May.
To underscore its support in Nova Credit and accelerate its global expansion, HSBC Ventures has made an investment of $10 million in the company.
Global Deployment Starts with Singapore
Historically, credit history has stopped at the border, preventing many financial services companies and lenders from being able to serve customers who have proven creditworthiness in their home country, but arrive credit invisible. Credit Passport® seamlessly and securely integrates into a financial institution’s credit application process, enabling applicants’ global credit records and score to be instantly accessed in just a few clicks.
HSBC Singapore is the first HSBC entity to launch the capability as part of the bank’s global rollout, also making it the first organization ever to implement Credit Passport® outside of the U.S., enabling it to instantly access the translated credit history of new-to-country consumers moving to Singapore, facilitating quicker access to credit for them.
Nova Credit and HSBC Singapore will initially use Credit Passport® to support the thousands of new to Singapore customers with credit history in India. The bank intends to expand the coverage of the solution to include customers with a credit history in Australia, the United Kingdom and the Philippines in 2022, and to more country bureaus in 2023, making it available to even more Singapore newcomers.
“Opening up a world of opportunity, sits at the core of HSBC’s purpose, and we’re always passionate about identifying new ways to solve problems faced by our International customers” said Taylan Turan, Group Head of Retail Banking and Strategy, Wealth and Personal Banking at HSBC. “Accessing credit in a new market can be a challenge and is something we’ve been helping customers with for years. We’re excited to be partnering with Nova Credit, to improve our ability to do this even more, with its innovative digital Credit Passport. We’re proud to be the first organisation to offer this to customers in Singapore.”
Additional Investment to Support Company’s Global Scale
As a testament to their belief in Nova Credit’s vision to stitch together the world’s financial system, HSBC Ventures has invested $10 million in the company. This investment will enable Nova Credit to support HSBC as they accelerate the deployment of Credit Passport® around the globe.
HSBC Ventures joins the likes of leading investors, including Kleiner Perkins, Canapi Ventures, General Catalyst and Index Ventures, and executives from Goldman Sachs, JPMorgan and Citi.
Since launching in the U.S. in 2016, Nova Credit has built relationships with credit bureaus in over 20 countries to gain consumer-permissioned access to over a billion credit profiles, and developed partnerships with big-name lenders such as American Express and Verizon.
“Nova Credit and its Credit Passport® product are at the forefront of financial innovation and we are delighted to bring this solution to our large international customer base,” said Catherine Zhou, Global Head of Ventures, Digital Innovation and Partnerships at HSBC. “Seeing the company’s success in reaching migrant communities over the past six years in the U.S., it is clear that Credit Passport® should be shared with a wider audience. This is the first step in an exciting journey, and we look forward to working with Nova Credit to bring scale to the business and its work towards financial inclusion.”
“Despite considerable globalization, our financial world remains far from borderless. This historic partnership with HSBC will bring the Credit Passport® to new parts of the world, unlocking new frontiers in the flow of financial information,” said Misha Esipov, co-founder and CEO of Nova Credit. “This partnership ensures that more people who cross borders can take their data with them, in a secure and compliant manner, and ultimately arrive and thrive in their new home.”
“This partnership and funding is the first step toward achieving a core goal of delivering the Credit Passport® globally: ensuring your financial identity is your own, no matter where you’re from or where you choose to live,” said Collin Galster, VP of International at Nova Credit. “We are honored to take this historic step in partnership with HSBC.”
To learn more about Credit Passport®, visit: www.novacredit.com/business/credit-passport
About Nova Credit
Nova Credit is a consumer-permissioned credit bureau with two products that help businesses make more fair and informed decisions on credit applicants. The Credit Passport® unlocks cross-border credit bureau data to help businesses underwrite new-to-country newcomer populations. The Cash Atlas™ provides greater insight into the cash flows of any applicant, including verifying their income with greater precision than alternatives. Businesses use these products to approve more applicants without taking on more risk, and consumers are empowered to put their best foot forward in their applications. The company’s differentiated data sources and proprietary analytics are used by leading organizations like American Express, Verizon, HSBC, SoFi, and Yardi. Nova Credit is backed by investors including Kleiner Perkins, General Catalyst, Index Ventures, and Canapi as well as executives from Goldman Sachs, JPMorgan, and Citi. Learn more at www.novacredit.com
About HSBC Holdings plc
HSBC Holdings plc, the parent company of HSBC, is headquartered in London. HSBC serves customer worldwide from offices in 63 countries and territories in its geographical regions: Europe, Asia, North America, Latin America, and Middle East and North Africa. With assets of US$2,985bn at 30 June 2022, HSBC is one of the world’s largest banking and financial services organisations.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220928005259/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
